top of page
kirabio-hero-3.jpg

Reprogramming cells to evade tumor suppression

 

Multiplex-edited. AI-guided. Built for tough tumors.

Our Science

Why most cell therapies fail
The tumor microenvironment (TME) suppresses immune cells and blocks durable function.

 

How we fix it
We reprogram cells to evade suppressive signals like TGFβ and   PD-1—preserving potency, even in the most hostile tumors.

 

The result
Resilient cell therapies, built for solid and blood cancers.

What sets our therapies apart

gene.png

Multiplex
Precision

Many edits, one step—designed for synergy, built for simplicity

cell.png

Off-the-Shelf Chassis

Donor-derived cells cut costs, shorten treatment timelines, and expand access

tme-kiragenbio-logo-white.png

Intrinsic

Resilience

Edits block suppression, preserving function and extending responses

The KiraLOGIC Platform

Why smarter edits matter

Most models rely on static readouts. We learn from real function.

 

How our platform works

KiraLOGIC predicts optimal multiplex edits using suppression data in a closed-loop system.

 

The result

Less wet lab burden, faster iteration, and more durable therapies.

How KiraLOGIC accelerates discovery

connections.png

Predictive Intelligence 

Models immune function using suppression-based readouts

funnel (1).png

Combinatorial Exploration

Screens billions of edits to find synergistic combinations

flow-diagram.png

Transferable Learning

Every program improves design speed across T, NK, and γδ cells

​Smarter design. Faster programs. Better outcomes.​

Our Support

2048-ventures.png
phoenix-logo_edited.png
zaka-vc.png
conscience.png
avf-logo_edited.png
incite-kiragenbio-logo-white.png
gaingels.png
lexi_ventures-kiragenbio-logo-white.png
pareto-kiragenbio-logo-white.png
joltvc.png

Our Recognitions

nucleate-logo.png

Nucleate Activator Program

Finalists in the 2024 Nucleate Activator Program final pitch showcase in Boston

HUCP Innovation Fund-logo.png
CBE Ventures-logo.png

HUCP Innovation Fund x CBE Ventures Competition

HUCP Innovation Fund x CBE Ventures Competition

Finalists in the 2023 Harvard Undergraduate Capital Partners Innovation Fund x Consulting, Bus., & Environment Venture Comp

President's Innovation Challenge

Presidents Innovation Challenge

Semi-finalists in the 2024 Harvard iLab's President's Innovation Challenge

The Termeer Foundation-logo-white.png

Co-founder and CEO, Aaron Edwards selected to be a Termeer Fellow, a values-driven leadership program for first time biotech founder/CEOs

Massachusetts Medical Device Development Center-logo-white.png

Finalists in the 2024 M2D2 $200k Grand Challenge

50Y_icon_red_fill_edited.jpg

Co-founder and CSO, Ryan Murray selected to be in 5050 Program, helping foster deep tech scientists/engineers become great founders.

Life Lab Pic.jpeg
bottom of page